108 related articles for article (PubMed ID: 18299461)
1. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
Taboada GF; Luque RM; Neto LV; Machado Ede O; Sbaffi BC; Domingues RC; Marcondes JB; Chimelli LM; Fontes R; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2008 Mar; 158(3):295-303. PubMed ID: 18299461
[TBL] [Abstract][Full Text] [Related]
2. Immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in Acromegaly.
Luo M; Yu J; Tang R
J Neurooncol; 2024 May; 167(3):415-425. PubMed ID: 38441839
[TBL] [Abstract][Full Text] [Related]
3. Correlation between tumor invasion and somatostatin receptor subtypes in acromegaly.
Zhang S; Yao S; Chen J; Akter F; Yang J; Zhu D; Zeng A; Chen W; Mao Z; Zhu Y; Wang H
J Neurosurg; 2024 Apr; 140(4):1019-1028. PubMed ID: 37856412
[TBL] [Abstract][Full Text] [Related]
4. Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly.
Marques-Pamies M; Gil J; Valassi E; Hernández M; Biagetti B; Giménez-Palop O; Martínez S; Carrato C; Pons L; Villar-Taibo R; Araujo-Castro M; Blanco C; Simón I; Simó-Servat A; Xifra G; Vázquez F; Pavón I; García-Centeno R; Zavala R; Hanzu FA; Mora M; Aulinas A; Vilarrasa N; Librizzi S; Calatayud M; de Miguel P; Alvarez-Escola C; Picó A; Sampedro M; Salinas I; Fajardo-Montañana C; Cámara R; Bernabéu I; Jordà M; Webb SM; Marazuela M; Puig-Domingo M
Front Endocrinol (Lausanne); 2023; 14():1269787. PubMed ID: 38027102
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor expression in thyroid disease.
Atkinson H; England JA; Rafferty A; Jesudason V; Bedford K; Karsai L; Atkin SL
Int J Exp Pathol; 2013 Jun; 94(3):226-9. PubMed ID: 23672766
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor (SSTR) expression and function in normal and leukaemic T-cells. Evidence for selective effects on adhesion to extracellular matrix components via SSTR2 and/or 3.
Talme T; Ivanoff J; Hägglund M; Van Neerven RJ; Ivanoff A; Sundqvist KG
Clin Exp Immunol; 2001 Jul; 125(1):71-9. PubMed ID: 11472428
[TBL] [Abstract][Full Text] [Related]
7. The Novel SSTR3 Agonist ITF2984 Exerts Antimitotic and Proapoptotic Effects in Human Non-Functioning Pituitary Neuroendocrine Tumor (NF-PitNET) Cells.
Di Muro G; Catalano R; Treppiedi D; Barbieri AM; Mangili F; Marra G; Di Bari S; Esposito E; Nozza E; Lania AG; Ferrante E; Locatelli M; Modena D; Steinkuhler C; Peverelli E; Mantovani G
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612419
[TBL] [Abstract][Full Text] [Related]
8. Molecular evidence and clinical importance of β-arrestins expression in patients with acromegaly.
Coelho MCA; Vasquez ML; Wildemberg LE; Vázquez-Borrego MC; Bitana L; Camacho AHDS; Silva D; Ogino LL; Ventura N; Chimelli L; Luque RM; Kasuki L; Gadelha MR
J Cell Mol Med; 2018 Apr; 22(4):2110-2116. PubMed ID: 29377493
[TBL] [Abstract][Full Text] [Related]
9. Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells.
Watt HL; Kumar U
Cancer Cell Int; 2006 Mar; 6():5. PubMed ID: 16519802
[TBL] [Abstract][Full Text] [Related]
10. Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using
Qin S; Yang Y; Zhang J; Yin Y; Liu W; Zhang H; Fan X; Yang M; Yu F
Mol Pharm; 2023 Nov; 20(11):5543-5553. PubMed ID: 37788300
[TBL] [Abstract][Full Text] [Related]
11. Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study.
von Arx C; Rea G; Napolitano M; Ottaiano A; Tatangelo F; Izzo F; Petrillo A; Clemente O; Di Sarno A; Botti G; Scala S; Tafuto S
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32859050
[TBL] [Abstract][Full Text] [Related]
12. Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide.
Casar-Borota O; Heck A; Schulz S; Nesland JM; Ramm-Pettersen J; Lekva T; Alafuzoff I; Bollerslev J
J Clin Endocrinol Metab; 2013 Nov; 98(11):E1730-9. PubMed ID: 24092823
[TBL] [Abstract][Full Text] [Related]
13. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.
Neto LV; Machado Ede O; Luque RM; Taboada GF; Marcondes JB; Chimelli LM; Quintella LP; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
J Clin Endocrinol Metab; 2009 Jun; 94(6):1931-7. PubMed ID: 19293270
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin and Somatostatin Receptors in Tumour Biology.
Kumar U
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203605
[TBL] [Abstract][Full Text] [Related]
15. Prolactin and Growth Hormone Signaling and Interlink Focused on the Mammosomatotroph Paradigm: A Comprehensive Review of the Literature.
Araujo-Castro M; Marazuela M; Puig-Domingo M; Biagetti B
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762304
[TBL] [Abstract][Full Text] [Related]
16. Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience.
Gadelha M; Marques NV; Fialho C; Scaf C; Lamback E; Antunes X; Santos E; Magalhães J; Wildemberg LE
J Clin Endocrinol Metab; 2023 Nov; 108(12):e1571-e1579. PubMed ID: 37357993
[TBL] [Abstract][Full Text] [Related]
17. Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas/somatotroph pituitary neuroendocrine tumors.
Yamato A; Nagano H; Gao Y; Matsuda T; Hashimoto N; Nakayama A; Yamagata K; Yokoyama M; Gong Y; Shi X; Zhahara SN; Kono T; Taki Y; Furuki N; Nishimura M; Horiguchi K; Iwadate Y; Fukuyo M; Rahmutulla B; Kaneda A; Hasegawa Y; Kawashima Y; Ohara O; Ishikawa T; Kawakami E; Nakamura Y; Inoshita N; Yamada S; Fukuhara N; Nishioka H; Tanaka T
Commun Biol; 2022 Nov; 5(1):1304. PubMed ID: 36435867
[TBL] [Abstract][Full Text] [Related]
18. Editorial: Resistance to Medical Therapy in Pituitary Tumors.
Auriemma RS; Gahete MD; Gatto F
Front Endocrinol (Lausanne); 2022; 13():861230. PubMed ID: 35282458
[No Abstract] [Full Text] [Related]
19. Direct effects of octreotide on osteoblast cell proliferation and function.
Vitali E; Palagano E; Schiavone ML; Mantovani G; Sobacchi C; Mazziotti G; Lania A
J Endocrinol Invest; 2022 May; 45(5):1045-1057. PubMed ID: 35020172
[TBL] [Abstract][Full Text] [Related]
20. N-glycosylation of somatostatin receptor type 2 protects rats from acute pancreatitis.
Huang M; Chen MM; Han D; Chen W; Xu F
Ann Transl Med; 2021 Nov; 9(22):1667. PubMed ID: 34988176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
